Branded acute coronary syndrome therapies to grab market share from generic drugs globally

The acute coronary syndrome (ACS) therapeutics market consists of around 30 marketed branded drugs and hundreds of generics.

While generic ACS drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60% of the total market due to the development and launch of novel pipeline products between 2015 and 2019. The US market for ACS therapeutics is the largest in terms of revenues, driven primarily by incidence rates of ACS and the healthcare reimbursement system. The European market follows closely with Germany, Italy and the UK offering the highest growth potential for both generic and branded dugs.

$33.54 billion sales in 2021

A new analysis from market research group Frost & Sullivan finds that the market earned revenues of $13.95 billion in 2014 and estimates this to reach $33.54 billion in 2021. The study covers anti-platelet, anti-thrombin, anti-hypertensives and cholesterol-lowering drugs, among others. Of these, anti-hypertensives and cholesterol-lowering drugs are emerging as the most promising therapy class owing to the development of drugs targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP).

Even though current therapeutics cater to most of the market needs, serious side effects such as statin intolerance and lack of therapies for treatment of thrombogenic atherosclerotic plaques represent opportunities for a newer class of drugs. Emerging drugs will augment existing therapeutics in addition to targeting orphan pathways for the treatment of ACS.